Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein

被引:73
作者
Haga, A
Niinaka, Y
Raz, A
机构
[1] Karmanos Canc Inst, Metastasis Res Program, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA
[3] Wayne State Univ, Sch Med, Dept Radiat Oncol, Detroit, MI 48202 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY | 2000年 / 1480卷 / 1-2期
关键词
autocrine motility factor; phosphorylation; migration; receptor;
D O I
10.1016/S0167-4838(00)00075-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phosphohexose isomerase (PHI) is a member of the ectoenzyme/exoenzyme family and plays a key role in both glycolysis and gluconeogenesis pathways. Upon secretion PHI acts as a cytokine with tumor autocrine motility factor (AMF), neuroleukin (NLK) and maturation factor (MF) functions. Signaling is initiated by its binding to a cell surface 78 kDa glycoprotein (gp78). However, since PHI protein is a 'leaderless' secretory protein, released from cells via a non-classical route(s), we questioned whether the molecule undergoes post-translation modification while retaining proper folding and maintaining intact enzymatic and motogenic activities. To address this, we have generated, expressed and isolated a recombinant human AMF (rhAMF). The rhAMF retained the biological activities of the native AMF, i.e., catalyzes phosphohexose isomerization and stimulated cell motility. Additionally, we show here that human PHI is phosphorylated at serine 185 by casein kinase II (CK II) and we provide experimental evidence suggesting that this phosphorylation is associated with secretion, thus providing insights for elucidating the intracellular signal transmission of cell response to stimulation by AMF/NLK/MF. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:235 / 244
页数:10
相关论文
共 40 条
  • [1] Study of the molecular defects in glucose phosphate isomerase-deficient patients affected by chronic hemolytic anemia
    Baronciani, L
    Zanella, A
    Bianchi, P
    Zappa, M
    Alfinito, F
    Iolascon, A
    Tannoia, N
    Beutler, E
    Sirchia, G
    [J]. BLOOD, 1996, 88 (06) : 2306 - 2310
  • [2] THE DIAGNOSTIC VALIDITY OF THE SERUM TUMOR-MARKER PHOSPHOHEXOSE ISOMERASE (PHI) IN PATIENTS WITH GASTROINTESTINAL, KIDNEY, AND BREAST-CANCER
    BAUMANN, M
    KAPPL, A
    LANG, T
    BRAND, K
    SIEGFRIED, W
    PATEROK, E
    [J]. CANCER INVESTIGATION, 1990, 8 (3-4) : 351 - 356
  • [3] BODANSKY O, 1954, CANCER, V7, P1200, DOI 10.1002/1097-0142(195411)7:6<1200::AID-CNCR2820070612>3.0.CO
  • [4] 2-9
  • [5] THE NEUROTROPHIC FACTOR NEUROLEUKIN IS 90-PERCENT HOMOLOGOUS WITH PHOSPHOHEXOSE ISOMERASE
    CHAPUT, M
    CLAES, V
    PORTETELLE, D
    CLUDTS, I
    CRAVADOR, A
    BURNY, A
    GRAS, H
    TARTAR, A
    [J]. NATURE, 1988, 332 (6163) : 454 - 455
  • [6] Neuroleukin mediated differentiation induction of myelogenous leukemia cells
    Chiao, JW
    Xu, W
    Seiter, K
    Feldman, E
    Ahmed, T
    [J]. LEUKEMIA RESEARCH, 1999, 23 (01) : 13 - 18
  • [7] GENETIC CONTROL OF 2 ELECTROPHORETIC VARIANTS OF GLUCOSEPHOSPHATE ISOMERASE IN MOUSE (MUS MUSCULUS)
    DELORENZO, RJ
    RUDDLE, FH
    [J]. BIOCHEMICAL GENETICS, 1969, 3 (02) : 151 - +
  • [8] SELECTIVE-INHIBITION OF A CYCLIC NUCLEOTIDE-INDEPENDENT PROTEIN-KINASE (G-TYPE CASEIN KINASE) BY NATURALLY OCCURRING GLYCOSAMINOGLYCANS
    FEIGE, JJ
    PIROLLET, F
    COCHET, C
    CHAMBAZ, EM
    [J]. FEBS LETTERS, 1980, 121 (01) : 139 - 142
  • [9] SERUM PHOSPHOHEXOSE ISOMERASE ACTIVITIES IN PATIENTS WITH COLORECTAL-CANCER
    FILELLA, X
    MOLINA, R
    JO, J
    MAS, E
    BALLESTA, AM
    [J]. TUMOR BIOLOGY, 1991, 12 (06) : 360 - 367
  • [10] GARCY RW, 1975, METHOD ENZYMOL, V41, P392